SAN FRANCISCO — Patients with stage III colon cancer assigned to Xelox realized a significant improvement in OS compared with those assigned to 5-FU plus leucovorin, according to final results from ...

The purpose of the study was to evaluate the cost-effectiveness of capecitabine plus oxaliplatin (XELOX) compared with 5-fluorouracil/folinic acid and oxaliplatin (FOLFOX4) as first-line or ...

Please provide your email address to receive an email when new articles are posted on . The addition of trastuzumab to the standard first-line regimen of capecitabine plus oxaliplatin created a highly ...

Analysis of correlation between oncogene mutation and response to chemotherapy in all RAS wild type metastatic colorectal cancer, using next-generation sequencing technology. This is an ASCO Meeting ...

A prospective multicenter phase II trial of total neoadjuvant therapy for locally advanced rectal cancer in JAPAN: ENSEMBLE-1 study. This is an ASCO Meeting Abstract from the 2024 ASCO ...

Colorectal cancer (CRC) is the second most common cause of death from cancer in industrialised countries (Jemal et al, 2003) and its incidence increases with age (Gatta et al, 1998). Because of a ...

Previous XELOX studies, conducted in patients where the disease has spread have shown that it is well tolerated with similar efficacy to the FOLFOX (oxaliplatin + 5-FU/LV) combination. 5,6,7 XELOX is ...

Roche Release: Results Show XELOX Provides Equivalent Overall Patient Survival Compared To FOLFOX In Advanced Colorectal Cancer NUTLEY, N.J., Jan. 22 -- Overall survival results from an international, ...

October 3, 2006 (Istanbul) — Experts at the 31st Congress of the European Society for Medical Oncology (ESMO) were calling for a change in the standard of care for first-line treatment of metastatic ...

After surgery for advanced gastric cancer, treatment with capecitabine and oxaliplatin (XELOX) cuts the risk for death by 34% over 5 years, compared with surgery alone, according to new data from the ...